

Struggling to find Cardizem at your pharmacy? Learn why Diltiazem can be hard to find in 2026, what's causing supply issues, and what you can do right now.
You called your pharmacy for a refill of Cardizem, and they told you it's out of stock. Now you're wondering: is it just my pharmacy, or is there a bigger problem? You're not imagining things. Many patients across the country have had trouble getting their hands on Diltiazem — the generic name for Cardizem — especially certain formulations. Let's break down what's going on and what you can do about it.
Cardizem (Diltiazem) is a calcium channel blocker used to treat high blood pressure, chest pain (angina), and certain heart rhythm problems like atrial fibrillation. It works by relaxing blood vessels and slowing the heart rate, which lowers blood pressure and reduces the heart's workload. Millions of Americans take Diltiazem every day, and it's been on the market for decades.
Cardizem comes in several forms: immediate-release tablets taken multiple times a day, and extended-release capsules and tablets (sold under brand names like Cardizem CD, Cardizem LA, Tiazac, and Cartia XT) that you take once daily. The variety of formulations is actually part of the story behind supply issues.
The most severe shortage involves Diltiazem injection, which hospitals use for emergency heart rhythm control. This shortage has been ongoing since June 2015 — making it one of the longest drug shortages in U.S. history. When Akorn Pharmaceuticals shut down in 2022, it removed one of only a few manufacturers from the market. As of 2026, Hikma and Pfizer are the primary suppliers, but production often can't keep up with demand.
While you probably take the oral form at home, the injectable shortage affects the broader Diltiazem supply chain. When hospitals can't get the IV version, some may shift to oral alternatives, which can create ripple effects at retail pharmacies.
Diltiazem is unusual because it comes in many different extended-release formulations that are not interchangeable. Cardizem CD, Cardizem LA, Tiazac, and Cartia XT all release the drug differently. Your pharmacy can't simply swap one for another without your doctor's approval. If your specific formulation is out of stock, you may need to wait or get a new prescription — even though other forms of Diltiazem are sitting on the shelf.
Although generic Diltiazem is made by several companies — including Teva, Mylan, Lupin, and Aurobindo — production of any specific strength or formulation can be disrupted by raw material shortages, quality control issues, or manufacturing delays. When one manufacturer has a problem, pharmacies that depend on that supplier can run dry until stock is replenished.
Pharmacies typically stock medications based on demand and insurance contracts. If a pharmacy's main wholesaler doesn't carry a particular generic Diltiazem formulation, or if insurance formulary changes push patients toward a different version, your local pharmacy might not keep your specific medication on hand. This is especially common with less popular strengths like 300 mg or 420 mg extended-release capsules.
If you're having trouble finding Cardizem or generic Diltiazem, here are some practical steps:
Cardizem supply issues are real — but they're not hopeless. The oral forms are generally available, even if your specific formulation takes some hunting. The injectable shortage is a long-standing hospital issue that may indirectly affect retail availability. The key is to plan ahead, use tools like Medfinder, and communicate with your doctor and pharmacist early if you're running low.
For a detailed look at the current supply situation, read our Cardizem shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.